Program
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010
Also written as “MK-2010” and “LM-299”.
Its studies are mostly in Neoplasms · Ovarian Neoplasms, led by 2 companies.
Drug pageAnti-PD-1/Anti-VEGF Bispecific Antibody MK-2010: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 33 open or running | phase 2since Feb 20, 2025 | Feb 20, 2025 | Sep 26, 2028phase 2 · NCT07793942 |
| Sino Biopharmaceuticalits history only | 11 open or running | phase 2since Oct 14, 2024 | Oct 14, 2024 | Dec 2026phase 2 · NCT06650566 |
- Named in Merck’s own pipeline as
MK-2010
, phase 2, as of Nov 2, 2026 (source).
Also a collaborator on its studies: Daiichi Sankyo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2024First study: phase 2 study in NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06650566 · 108 planned · Australia, China
- Feb 20, 2025Merck’s first study: phase 2 study in Ovarian Cancer RecurrentNew to MerckMerck · NCT06843447 · 605 planned · United States, Australia, Canada and more
- Aug 21, 20262 phase 2 studiesMerck · NCT07785609, NCT07793942
Ahead
- Dec 2026Primary completion: phase 2 study in NeoplasmsSino Biopharmaceutical · NCT06650566
- Sep 26, 2028Primary completion: phase 2 study in Malignant NeoplamMerck · NCT07793942
- Mar 27, 2029Primary completion: phase 2 study in Ovarian Cancer RecurrentMerck · NCT06843447
- Sep 30, 2031Primary completion: phase 2 study in NeoplasmsMerck · NCT07785609
TargetBeta
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon a…”NCIt, read by Claude
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| tivunatamig | Pfizer | phase 3 | 15 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rule | wigen-biomedicine-technology-shanghai-co-ltd | phase 2 | 2 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rule | compass-therapeutics | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07793942Malignant Neoplam · United States, Canada, Switzerland | 2 | Recruiting | Merck | Sep 26, 2028 | 480 |
| NCT07785609Neoplasms · United States, Hong Kong, Switzerland | 2 | Recruiting | Merck | Sep 30, 2031 | 200 |
| NCT06843447Ovarian Cancer Recurrent · United States, Australia, Canada and more | 2 | Recruiting | Merck | Mar 27, 2029 | 605 |
| NCT06650566Neoplasms · Australia, China | 2 | Recruiting | Sino Biopharmaceutical | Dec 2026 | 108 |
How it is read
Names in the registry
- “MK-2010”, 3 entries
- “LM-299”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 2 studies
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.